159 related articles for article (PubMed ID: 28150753)
1. Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells.
Liang Z; Li W; Liu J; Li J; He F; Jiang Y; Yang L; Li P; Wang B; Wang Y; Ren Y; Yang J; Luo Z; Vaziri C; Liu P
Sci Rep; 2017 Feb; 7():41776. PubMed ID: 28150753
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth.
Li J; Liu J; Liang Z; He F; Yang L; Li P; Jiang Y; Wang B; Zhou C; Wang Y; Ren Y; Yang J; Zhang J; Luo Z; Vaziri C; Liu P
Cell Death Dis; 2017 Mar; 8(3):e2673. PubMed ID: 28300827
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin exerts anti-hepatitis B virus activity by inhibiting expression of minichromosome maintenance protein 7 in HepG2.2.15 cells.
Li W; Cao F; Li J; Wang Z; Ren Y; Liang Z; Liu P
Mol Med Rep; 2016 Dec; 14(6):5334-5342. PubMed ID: 27779671
[TBL] [Abstract][Full Text] [Related]
4. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E
Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
6. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Lim SC; Kim HS; Kim TH; Lee KY; Ahn SG; Yoon JH; Kang KW
Breast Cancer Res Treat; 2011 Nov; 130(1):73-83. PubMed ID: 21170675
[TBL] [Abstract][Full Text] [Related]
7. EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation.
Chen S; Yao F; Xiao Q; Liu Q; Yang Y; Li X; Jiang G; Kuno T; Fang Y
Mol Med Rep; 2018 Feb; 17(2):2642-2650. PubMed ID: 29207119
[TBL] [Abstract][Full Text] [Related]
8. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
Li F; Miao L; Xue T; Qin H; Mondal S; Thompson PR; Coonrod SA; Liu X; Zhang X
J Exp Clin Cancer Res; 2019 Oct; 38(1):414. PubMed ID: 31601253
[TBL] [Abstract][Full Text] [Related]
10. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
11. The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity.
Kitajima S; Yoshida A; Kohno S; Li F; Suzuki S; Nagatani N; Nishimoto Y; Sasaki N; Muranaka H; Wan Y; Thai TC; Okahashi N; Matsuda F; Shimizu H; Nishiuchi T; Suzuki Y; Tominaga K; Gotoh N; Suzuki M; Ewen ME; Barbie DA; Hirose O; Tanaka T; Takahashi C
Oncogene; 2017 Sep; 36(36):5145-5157. PubMed ID: 28481867
[TBL] [Abstract][Full Text] [Related]
12. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
13. Elevated CRB3 expression suppresses breast cancer stemness by inhibiting β-catenin signalling to restore tamoxifen sensitivity.
Li P; Feng C; Chen H; Jiang Y; Cao F; Liu J; Liu P
J Cell Mol Med; 2018 Jul; 22(7):3423-3433. PubMed ID: 29602199
[TBL] [Abstract][Full Text] [Related]
14. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Im JH; Yang JW; Choi MC; Lim SC; Lee KY; Kim YM; Yoon JH; Kang KW
Oncotarget; 2016 Mar; 7(12):13902-16. PubMed ID: 26418898
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
Bekele RT; Venkatraman G; Liu RZ; Tang X; Mi S; Benesch MG; Mackey JR; Godbout R; Curtis JM; McMullen TP; Brindley DN
Sci Rep; 2016 Feb; 6():21164. PubMed ID: 26883574
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
17. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Hiscox S; Morgan L; Green TP; Barrow D; Gee J; Nicholson RI
Breast Cancer Res Treat; 2006 Jun; 97(3):263-74. PubMed ID: 16333527
[TBL] [Abstract][Full Text] [Related]
18. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Moriai R; Tsuji N; Moriai M; Kobayashi D; Watanabe N
Breast Cancer Res Treat; 2009 Sep; 117(2):261-71. PubMed ID: 18815881
[TBL] [Abstract][Full Text] [Related]
19. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
Lü M; Ding K; Zhang G; Yin M; Yao G; Tian H; Lian J; Liu L; Liang M; Zhu T; Sun F
Sci Rep; 2015 Mar; 5():8735. PubMed ID: 25736597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
